Baird raised the firm’s price target on CVS Health (CVS) to $92 from $82 and keeps an Outperform rating on the shares. The firm updated its model and believes its bull thesis remains intact.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $93 from $89 at Morgan Stanley
- CVS Health price target raised to $101 from $99 at Piper Sandler
- CVS Health price target raised to $93 from $87 at Barclays
- CVS Health price target raised to $97 from $96 at UBS
- CVS Health: Strong Financial Outlook and Strategic Initiatives Drive Buy Rating